Attached files
| file | filename |
|---|---|
| EX-31.1 - CERTIFICATION OF CEO PURSUANT TO RULES 13A-14(A) AND 15D-14(A) - Jazz Pharmaceuticals plc | jazzq42020ex311.htm |
| EX-32.1 - CERTIFICATIONS OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350 - Jazz Pharmaceuticals plc | jazzq42020ex321.htm |
| EX-31.2 - CERTIFICATION OF CFO PURSUANT TO RULES 13A-14(A) AND 15D-14(A) - Jazz Pharmaceuticals plc | jazzq42020ex312.htm |
| EX-21.1 - LIST OF SUBSIDIARIES - Jazz Pharmaceuticals plc | jazzq42020ex211.htm |
| EX-10.33D - CASH BONUS PLAN (IRELAND AND OTHER) - Jazz Pharmaceuticals plc | jazzq42020ex1033d.htm |
| EX-10.33C - CASH BONUS PLAN U.S. - Jazz Pharmaceuticals plc | jazzq42020ex1033c.htm |
| EX-10.12 - AMENDED AND RESTATED LICENSE AGREEMENT - Jazz Pharmaceuticals plc | jazzq42020ex1012.htm |
| EX-10.8 - MANUFACTURING SERVICES AGREEMENT - Jazz Pharmaceuticals plc | jazzq42020ex108.htm |
| EX-4.7 - DESCRIPTION OF SHARE CAPITAL - Jazz Pharmaceuticals plc | jazzq42020ex47.htm |
| 10-K - 10-K - Jazz Pharmaceuticals plc | jazz-20201231.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Jazz Pharmaceuticals plc
We consent to the incorporation by reference in the registration statements (No. 333-249807, No. 333-236636, No. 333‑229889, No. 333-224757, No. 333-216338, No. 333-209767, No. 333-202269, No. 333-194131, No. 333-186886 and No. 333-179075) on Form S-8 of Jazz Pharmaceuticals plc of our reports dated February 23, 2021, with respect to the consolidated balance sheets of Jazz Pharmaceuticals plc as of December 31, 2020 and 2019, the related consolidated statements of income, comprehensive income, shareholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2020, and the related notes and financial statement schedule at Item 15(a)2, and the effectiveness of internal control over financial reporting as of December 31, 2020, which reports appear in the December 31, 2020 annual report on Form 10‑K of Jazz Pharmaceuticals plc.
/s/ KPMG
KPMG
Dublin, Ireland
February 23, 2021